Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CASR | P41180 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639888 | 1.00 | PKM (0.63) | PKMCYP2D6CASRNPC1ATM | |
| SCHEMBL22639907 | 0.86 | CYP2D6 (0.74) | CYP2D6NPC1MEN1HTTKMT2A | |
| SCHEMBL22640159 | 0.86 | CYP2D6 (0.74) | CYP2D6NPC1MEN1HTTKMT2A | |
| SCHEMBL22639913 | 0.81 | PKM (0.52) | PKMCYP2D6MEN1KMT2ASLC2A1 | |
| SCHEMBL22639837 | 0.81 | PKM (0.52) | PKMCYP2D6MEN1KMT2ASLC2A1 | |
| Hydrochloric Acid SCHEMBL5515243 | 0.80 | CASR (0.80) | CYP2D6CASRALDH1A1SLC6A2 | |
| SCHEMBL14383074 | 0.80 | CASR (0.80) | CYP2D6CASRATMSLC6A2 | |
| SCHEMBL12215557 | 0.79 | SLC2A1 (0.57) | PKMCASRMEN1HTTKMT2A | |
| Hydrochloric Acid SCHEMBL5518892 | 0.79 | CASR (0.78) | CYP2D6CASRATMSLC6A2 | |
| SCHEMBL1195641 | 0.78 | DRD2 (0.54) | NPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | PKM 846/4885CYP2D6 3360/4885CASR 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.